Related Experiment Video
Updated: Jul 27, 2025

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
The role of stakeholder involvement in the evolving EU HTA process:
Lauren Van Haesendonck1, Jörg Ruof2,3, Thomas Desmet1,4
1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Ensuring stakeholder involvement is crucial for EU HTA harmonization. This study found key groups perceived their involvement lower than others rated them, highlighting a need for improved engagement strategies in the EU HTA process.
Area of Science:
- Health economics and outcomes research
- Regulatory science
- Health policy
Background:
- The European Union (EU) Health Technology Assessment (HTA) harmonization process requires effective stakeholder engagement for successful implementation.
- Understanding the current and desired roles of various stakeholders is essential for optimizing this process.
Purpose of the Study:
- To assess the current involvement of key stakeholders in the EU HTA framework.
- To determine suggested future roles, identify challenges, and highlight efficient engagement methods for stakeholders.
- To compare self-perceived involvement with external ratings from HTA bodies, payers, and policymakers.
Main Methods:
- A multi-step procedure was used to develop and circulate a survey to diverse stakeholders within the EU HTA framework.
- Key stakeholder groups included patients, clinicians, regulatory representatives, and Health Technology Developers.
- Two survey versions were used: self-rating by key stakeholders and external rating by HTA bodies, payers, and policymakers. Analyses included predefined statistical and qualitative assessments, leading to the development of a RACI chart.
Main Results:
- Fifty-four responses were received from patients, clinicians, regulators, Health Technology Developers, HTA bodies, payers, and policymakers.
- Self-perceived involvement scores were consistently lower across all key stakeholder groups compared to external ratings.
- A RACI (Responsible/Accountable/Consulted/Informed) chart was developed based on survey insights to define stakeholder roles in the EU HTA process.
Conclusions:
- Significant efforts and a dedicated research agenda are necessary to ensure adequate involvement of key stakeholders in the evolving EU HTA harmonization process.
- Addressing the discrepancy between self-perceived and externally perceived involvement is critical for enhancing stakeholder contribution.
- The findings provide a foundation for developing targeted strategies to improve stakeholder engagement and the overall effectiveness of EU HTA harmonization.
More Related Videos
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Ethical Dilemmas II
Preclinical Development: Overview
Standards of Care II

